• Quarterly sales of $4.4 million, in line with prior year
• Organisational changes implemented to align with current strategy
• Ramp-up of US sales impacted by customer processes and market uncertainty
• Commenced development of automated, high-throughput solution

Genetic Signatures Ltd reported quarterly sales of $4.4 million for Q4 FY2025, an increase of 52% from the previous quarter and in line with the prior corresponding period, reflecting higher testing rates typically experienced during the Australian winter respiratory season. Receipts from customers for the quarter were $3.6 million, a 67.5% increase on the prior corresponding period. The company recorded a net operating cash outflow of $5.9 million for the quarter, reflecting higher investment in inventory for the Australian winter respiratory season. During the quarter, Genetic Signatures implemented organisational changes, including changes to US leadership and a focused reorganisation of the US team, to better align with the company's current strategy and needs. The ramp-up of US sales has been impacted by prospective customers' internal processes, competing priorities, preference for enhanced workflow and uncertainty in the US healthcare environment. However, the company subsequently signed an additional US contract with a large integrated healthcare organisation. The company also commenced the development of an automated, high-throughput solution through a customisation of commercially available instruments in partnership with Tecan Group and Repado. Genetic Signatures maintained strong engagement with molecular experts globally, with key opinion leaders presenting at leading conferences to showcase the benefits of the company's molecular diagnostic solutions. The company ended the quarter with a strong cash balance of $30.9 million.

Genetic Signatures remains committed to maintaining and growing its footprint in Australia, while expanding its market presence globally, with a particular focus on the United States and the United Kingdom. The company's strong cash position provides the resources to continue supporting its team and commercial initiatives, while also driving innovation across assay development, workflow optimisation, instrumentation, and software enhancements.